Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
anakinra interleukin 1 receptor type 1 NA Successful target TTD , DGIDB Rheumatoid Arthritis[MeSHID:D001172]
Chronic Infantile Neurological
Cutaneous
and Articular Syndrome[MeSHID:D056587]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
17.24 approved antagonist
anakinra interleukin-1 receptor type 1 biotech NA drugbank , DGIDB Rheumatoid Arthritis[MeSHID:D001172]
Chronic Infantile Neurological
Cutaneous
and Articular Syndrome[MeSHID:D056587]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]
Disease[MeSHID:D004194]
17.24 approved antagonist
anakinra interleukin-1 receptor type 1 biotech NA drugbank , DGIDB Rheumatoid Arthritis[MeSHID:D001172]
Chronic Infantile Neurological
Cutaneous
and Articular Syndrome[MeSHID:D056587]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
17.24 approved antagonist
anakinra interleukin 1 receptor type 1 NA Successful target TTD , DGIDB Rheumatoid Arthritis[MeSHID:D001172]
Chronic Infantile Neurological
Cutaneous
and Articular Syndrome[MeSHID:D056587]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]
Disease[MeSHID:D004194]
17.24 approved unknown
anakinra interleukin 1 receptor type 1 NA Successful target TTD , DGIDB Rheumatoid Arthritis[MeSHID:D001172]
Chronic Infantile Neurological
Cutaneous
and Articular Syndrome[MeSHID:D056587]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]
Disease[MeSHID:D004194]
17.24 approved antagonist
anakinra interleukin 1 receptor type 1 NA Successful target TTD , DGIDB Rheumatoid Arthritis[MeSHID:D001172]
Chronic Infantile Neurological
Cutaneous
and Articular Syndrome[MeSHID:D056587]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
17.24 approved unknown
click here to return to the previous page